|
HepC Newsletter
|
Dema-@aol.com
|
Jul 07, 2009 06:11 PDT
|
NATAP http://natap.org/
_______________________________________________
_EASL 44th Annual Meeting (European Association for the Study of the
Liver)_ (http://www.natap.org/2009/EASL/EASL.htm)
April 22-26, 2009
Copenhagen, Denmark
EASL 44th Annual Meeting
(European Association for the Study of the Liver)
April 22-26, 2009
Copenhagen, Denmark
* _Early EPO Use Increased SVR Rates and Reduced Discontinuation
Rate !_ (http://www.natap.org/2009/EASL/EASL_91.htm) (05/29/09)
* _New HCV Drug Report: "Using a new palette of treatment options to
paint the portrait of cure for patients infected with hepatitis C on our
clinical canvas." _ (http://www.natap.org/2009/EASL/EASL_90.htm) - written
by Robert Gish MD - (05/28/09)
* _EXTENDED TREATMENT DURATION TO 72 Weeks IN CHRONIC HEPATITIS C
GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY
(SUCCESS)_ (http://www.natap.org/2009/EASL/EASL_89.htm) - (05/27/09)
* _BI 201335, a potent HCV NS3 protease inhibitor, in
treatment-naïve and -experienced chronic HCV genotype-1 infection: genotypic and
phenotypic analysis of the NS3 protease domain_
(http://www.natap.org/2009/EASL/EASL_88.htm) - (05/27/09)
* _Preclinical characterization of PRO 206, an orally active HCV
entry inhibitor _ (http://www.natap.org/2009/EASL/EASL_87.htm) - (05/27/09)
* _EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 µg/WEEK IN
COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE 1 PATIENTS - IMPACT Of
CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY _
(http://www.natap.org/2009/EASL/EASL_86.htm) - (05/14/09)
* _EASL Analysis, New Oral HCV Drugs What's Expected _
(http://www.natap.org/2009/EASL/EASL_85.htm) - (05/14/09)
* _Histologic Outcomes in Hepatitis C-Infected Patients With
Breakthrough or Relapse to Interferon-Based Treatments: there was a positive
correclation between viral response and improved fibrosis _
(http://www.natap.org/2009/EASL/EASL_84.htm) - (05/13/09)
* _BASELINE CHARACTERISTICS AND WEEK 4 RESPONSE AMONG CHRONIC
HEPATITIS C PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 OR 4: INTERIM RESULTS OF
THE PROPHESYS TRIAL _ (http://www.natap.org/2009/EASL/EASL_83.htm) -
(05/13/09)
* _Identifying Patients Infected With HCV Genotype 1 Who May Benefit
From Extended Peginterferon Alfa-2a/Ribavirin Therapy Beyond 48 Weeks _
(http://www.natap.org/2009/EASL/EASL_82.htm) - (05/13/09)
* _IDENTIFYING PATIENTS WITH A HIGH LIKELIHOOD OF ACHIEVING AN SVR
FOLLOWING RE-TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN: USE
OF POSITIVE PROGNOSTIC FACTORS (PPF'S) _
(http://www.natap.org/2009/EASL/EASL_81.htm) - (05/12/09)
* _Ursodeoxychic Acid Improved NASH, Not So Sure About Rosiglitazone
_ (http://www.natap.org/2009/EASL/EASL_80.htm) - (05/12/09)
* _Single and Multiple-Dose Assessments of the Safety and
Pharmacokinetics of SCH 900518 and Its Effect on the Pharmacokinetics of Midazolam in
Healthy Subjects _ (http://www.natap.org/2009/EASL/EASL_79.htm) -
(05/12/09)
* _Preclinical Characterization of SCH 900518,A Novel
Mechanism-Based Inhibitor of HCV NS3 Protease _
(http://www.natap.org/2009/EASL/EASL_78.htm) - (05/12/09)
* _Individualized treatment duration with peginterferon alfa-2b and
ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with
undetectable HCV-RNA early during therapy (INDIV-2 study)_
(http://www.natap.org/2009/EASL/EASL_77.htm) - (05/12/09)
* _A Regional Gastrointestinal Absorption Study of the HCV NS3
Protease Inhibitor SCH 900518 in Healthy Volunteers: "remote-controlled drug del
ivery device that delivers any form of drug to key regions of the human
gastrointestinal (GI) tract." _ (http://www.natap.org/2009/EASL/EASL_76.htm) -
(05/12/09)
* _Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel
and Potent Non-Nucleoside HCV Polymerase Inhibitor _
(http://www.natap.org/2009/EASL/EASL_75.htm) - (05/11/09)
* _Preclinical Profiles of IDX136 and IDX316, Two Novel Macrocyclic
HCV Protease Inhibitors _ (http://www.natap.org/2009/EASL/EASL_74.htm) -
(05/11/09)
* _IDENTIFICATION AND PROFILE OF POTENT AND SELECTIVE INHIBITORS OF
HCV NS5A PROTEIN _ (http://www.natap.org/2009/EASL/EASL_73.htm) - (05/11/09)
* _Albuferon vs Pegasys Genotype 2/3 _
(http://www.natap.org/2009/EASL/EASL_72.htm) - (05/07/09)
* _Albuferon vs Pegasys Genotype 1 _
(http://www.natap.org/2009/EASL/EASL_54.htm) - (05/07/09)
* _Co Press Release: Biolex presents Locteron US Phase 2a hepatitis
C data at EASL _ (http://www.natap.org/2009/EASL/EASL_71.htm) - (05/07/09)
* _Identification and Characterization of VCH-222, a Novel Potent
and Selective Non-Nucleoside HCV Polymerase Inhibitor _
(http://www.natap.org/2009/EASL/EASL_70.htm) - (05/07/09)
* _Activity & Genotypic and Phenotypic Analysis of HCV NS5B Variants
Selected from Patients Treated with VCH-916 _
(http://www.natap.org/2009/EASL/EASL_69.htm) - (05/07/09)
* _Randomized Trial Comparing Systemic and Local Reactions to
Controlled-release Interferon Alpha2b and Pegylated-interferon Alpha2b in
Hepatitis C Patients Who Failed Prior Treatment _
(http://www.natap.org/2009/EASL/EASL_68.htm) - (05/07/09)
* _Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of
Nitazoxanide with Peginterferon Alfa-2a and Ribavirin in Nonresponders (NR)
with Chronic HCV Genotype 1: Week 28 Interim Analysis _
(http://www.natap.org/2009/EASL/EASL_67.htm) - (05/07/09)
* _Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of
Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve
Patients: Interim Analysis Shows Increase in EVR _
(http://www.natap.org/2009/EASL/EASL_66.htm) - (05/07/09)
* _Preclinical Pharmacokinetic and ADME Characterization of VCH-222,
a Novel Non-Nucleoside HCV NS5B Polymerase Inhibitor from Vertex/ViroChem
_ (http://www.natap.org/2009/EASL/EASL_65.htm) - (05/07/09)
* _IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor:
Results of a First-in-Man Safety and Pharmacokinetic Study _
(http://www.natap.org/2009/EASL/EASL_64.htm) - (05/07/09)
* _Antiviral Activity of the Liver-Targeted Nucleotide HCV
Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside
Metabolite in HCV-infected Chimpanzees _
(http://www.natap.org/2009/EASL/EASL_63.htm) - (05/07/09)
* _Evolution of Viral Load and Genome Sequence in a Clinical Trial
of Tenofovir/Emtricitabine Combination Versus Tenofovir Monotherapy for
Patients with Previous Adefovir Dipivoxil Failure _
(http://www.natap.org/2009/EASL/EASL_62.htm) - (05/07/09)
* _Characteristics of HBeAg-Positive Patients with HBsAg
Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF) _
(http://www.natap.org/2009/EASL/EASL_61.htm) - (05/07/09)
* _Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate
Therapy in Lamivudine Experienced Patients _
(http://www.natap.org/2009/EASL/EASL_60.htm) - (05/06/09)
* _Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil
Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with
Chronic Hepatitis B (CHB) _ (http://www.natap.org/2009/EASL/EASL_59.htm) -
(05/06/09)
* _Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF
(FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with
Persistent Viral Replication Receiving Adefovir Dipivoxil _
(http://www.natap.org/2009/EASL/EASL_58.htm) - (05/06/09)
* _BASELINE HBsAg LEVEL PREDICT HBsAg LOSS IN CHRONIC HEPATITIS B
PATIENTS TREATED WITH A COMBINATION OF PEGINTERFERON ALFA-2A AND ADEFOVIR: AN
INTERIM ANALYSIS _ (http://www.natap.org/2009/EASL/EASL_57.htm) -
(05/06/09)
* _HBsAg Decline Appears To Predict Clearance- Increasing Rates of
HBsAg Clearance and Seroconversion in Patients With HBeAg-Negative Disease
Treated With Peginterferon Alfa-2a ± Lamivudine: Results of 5-Year
Post-Treatment Follow-up _ (http://www.natap.org/2009/EASL/EASL_56.htm) - (05/06/09)
* _Hepatitis B Virus Drugs in Pregnancy: Findings from the
Antiretroviral Pregnancy Registry _ (http://www.natap.org/2009/EASL/EASL_55.htm) -
(05/06/09)
* _Pharmacokinetics, Safety and Tolerability of the HCV Polymerase
Inhibitor ABT-333 Following Multiple Ascending Doses and Effect of
Co-Administration of Ketoconazole in Healthy Subjects _
(http://www.natap.org/2009/EASL/EASL_53.htm) - (05/05/09)
* _Characterization of Resistance Mutations Selected In Vitro by
Non-Nucleoside HCV Polymerase Inhibitors ABT-333 and ABT-072 _
(http://www.natap.org/2009/EASL/EASL_52.htm) - (05/05/09)
* _US Hepatitis C Burden Assessment from a Transmission Model: HCV
burden reduced by new HCV drugs _
(http://www.natap.org/2009/EASL/EASL_50.htm) - (05/05/09)
* _Pharmacokinetics and Tolerability of the HCV Polymerase Inhibitor
ABT-333 Following Single Ascending Doses in Healthy Adult Volunteers _
(http://www.natap.org/2009/EASL/EASL_49.htm) - (05/05/09)
* _Safety, Tolerability and Pharmacokinetics of the HCV Polymerase
Inhibitor VCH-222 Following Single Dose Administration in Healthy Volunteers
and Antiviral Activity in HCV-infected Individuals _
(http://www.natap.org/2009/EASL/EASL_48.htm) - (05/05/09)
* _On-Treatment Monitoring of HBsAg Levels to Predict Response to
Peginterferon Alfa-2a in Patients With HBeAg-Positive Chronic Hepatitis B _
(http://www.natap.org/2009/EASL/EASL_47.htm) - (05/05/09)
* _Safety, Tolerability, and Pharmacokinetics of GS-9450 in Healthy
Male and Female Volunteers_ (http://www.natap.org/2009/EASL/EASL_46.htm) -
(05/05/09)
* _Abbott/Enanta - Potent HCV Protease Inhibitors with the Potential
for Once-daily Dosing and Broad Genotype Coverage _
(http://www.natap.org/2009/EASL/EASL_45.htm) - (05/05/09)
* _Preclinical Characterization of ABT-072: A Novel Non-Nucleoside
HCV Polymerase Inhibitor _ (http://www.natap.org/2009/EASL/EASL_44.htm) -
(05/05/09)
* _Preclinical Potency, Pharmacokinetic and ADME Characterization of
ABT-333, A Novel Non-Nucleoside HCV Polymerase Inhibitor _
(http://www.natap.org/2009/EASL/EASL_43.htm) - (05/05/09)
* _2 Schering HCV Protease Inhibitors; Final Results of Boceprevir
Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared
to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients _
(http://www.natap.org/2009/EASL/EASL_42.htm) - (05/04/09)
* _Tenofovir 2 Years Safety, Efficacy & Resistance in Patients with
Cirrhosis_ (http://www.natap.org/2009/EASL/EASL_41.htm) - (05/01/09)
* _EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN
COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY
NULL-RESPONDER GENOTYPE 1 HCV PATIENTS _
(http://www.natap.org/2009/EASL/EASL_40.htm) - (05/01/09)
* _SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS
MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND
TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS _
(http://www.natap.org/2009/EASL/EASL_39.htm) - (04/30/09)
* _PegIntron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV
Patients Who Failed to Respond to Interferon/Ribavirin (IR) Therapy: Final
Results of the EPIC3 Cirrhosis Maintenance Trial _
(http://www.natap.org/2009/EASL/EASL_38.htm) - (04/30/09)
* _HCV SPRINT-1: Final Results SVR 24 NS3 Protease Inhibitor
Boceprevir plus PegIFN alpha-2b/Ribavirin HCV 1 Treatment Naïve Patients_
(http://www.natap.org/2009/EASL/EASL_37.htm) - (04/30/09)
* _Antiviral Activity and Safety of ITMN-191 (R7227) in Combination
with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis
C Virus_ (http://www.natap.org/2009/EASL/EASL_36.htm) - (04/29/09)
* _Antiviral activity and safety of TMC435 combined with
peginterferon a-2a and ribavirin in patients with genotype-1 hepatitis C infection who
failed previous IFN-based therapy_
(http://www.natap.org/2009/EASL/EASL_35.htm) - (04/29/09)
* _Antiviral Activity of Filibuvir in Combination with Pegylated
Interferon Alfa-2a and Ribavirin for 28 Days in Treatment-Naive Patients
Chronically Infected with HCV Genotype 1_
(http://www.natap.org/2009/EASL/EASL_34.htm) - (04/29/09)
* _Subgroup Analysis Confirms Efficacy, Safety of Sorafenib in
Patients With Late-Stage Liver Cancer: Presented at EASL _
(http://www.natap.org/2009/EASL/EASL_33.htm) - (04/29/09)
* _A FIRST CLINICAL TRIAL OF THERAPEUTIC VACCINATION USING NAKED DNA
DELIVERED BY IN VIVO ELECTROPORATION SHOWS ANTIVIRAL EFFECTS IN PATIENTS
WITH CHRONIC HEPATITIS C_ (http://www.natap.org/2009/EASL/EASL_32.htm) -
(04/29/09)
* _Entecavir Maintains a High Genetic Barrier to HBV Resistance
Through 6 Years in Naive Patients _
(http://www.natap.org/2009/EASL/EASL_31.htm) - (04/29/09)
* _Entecavir (ETV) Therapy in Chronic Hepatitis B Patients
Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or
Relapse Off-Treatment_ (http://www.natap.org/2009/EASL/EASL_30.htm) -
(04/29/09)
* _Safety, Tolerability, and Pharmacokinetics after Single and
Multiple Doses of MK-3281 in Healthy Subjects _
(http://www.natap.org/2009/EASL/EASL_28.htm) - (04/28/09)
* _MK-7009 Significantly Improves Rapid Viral Response (RVR) in
Combination with Pegylated Interferon Alfa-2a and Ribavirinin Patients with
Chronic Hepatitis C (CHC) Genotype 1 Infection _
(http://www.natap.org/2009/EASL/EASL_27.htm) - (04/28/09)
* _Metabolic Syndrome Hikes Mortality in Hepatitis C _
(http://www.natap.org/2009/EASL/EASL_26.htm) - (04/28/09)
* _Ground-Breaking Combination of 2 All-Oral Agents Demonstrates
Potential as Hepatitis C Treatment Regimen (ITMN-191 protease + R7128 NRTI) _
(http://www.natap.org/2009/EASL/EASL_25.htm) - (04/28/09)
* _FDA Regulations for HCV Drug Development - are they too Strict? _
(http://www.natap.org/2009/EASL/EASL_24.htm) - (04/28/09)
* _Can Peginterferon and Ribavirin Be Eliminated from Therapy _
(http://www.natap.org/2009/EASL/EASL_23.htm) - (04/28/09)
* _Roche and Pharmasset start phase IIb clinical trial of R7128
nucleoside polymerase inhibitor for chronic hepatitis C _
(http://www.natap.org/2009/EASL/EASL_22.htm) - (04/28/09)
* _OPERA-1 trial (Study TMC435-C201): interim analysis of safety and
antiviral activity of TMC435 in treatment-naive genotype-1 HCV patients_
(http://www.natap.org/2009/EASL/EASL_21.htm) - (04/28/09)
* _TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR
NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND
RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY _
(http://www.natap.org/2009/EASL/EASL_20.htm) - (04/28/09)
* _Potent Antiviral Activity With A Nucleoside Polymerase (R7128)
And Protease (R7227/ITMN-191) Inhibitor Combination in HCV Genotype 1:
Initial Safety, Pharmacokinetics, And Virologic Results From INFORM-1 _
(http://www.natap.org/2009/EASL/EASL_19.htm) - (04/28/09)
* _EASL Day 3 Saturday _
(http://www.natap.org/2009/EASL/EASL_18.htm) - (04/28/09)
* _HCV Protease ITMN-191 + Peg/RBV for 14 Days - safety, antiviral
activity _ (http://www.natap.org/2009/EASL/EASL_17.htm) - (04/28/09)
* _SCH-900518 New Schering Protease Inhibitor Monotherapy & with
Peg/RBV 7-14 days _ (http://www.natap.org/2009/EASL/EASL_16.htm) - (04/28/09)
* _Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128,
Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic
Hepatitis C _ (http://www.natap.org/2009/EASL/EASL_15.htm) - (04/28/09)
* _Peg-Interferon lambda + Ribavirin 4 Weeks _
(http://www.natap.org/2009/EASL/EASL_14.htm) - (04/28/09)
* _Telaprevir Effective for Genotype 2 But Not For Genotype 3 _
(http://www.natap.org/2009/EASL/EASL_13.htm) - (04/27/09)
* _Maintenance Therapy: we don't know if it provides benefit _
(http://www.natap.org/2009/EASL/EASL_12.htm) - (04/27/09)
* _HIV positive and HIV negative patients have similar survival
rates following liver transplant _ (http://www.natap.org/2009/EASL/EASL_11.htm)
- (04/27/09)
* _Anadys shares plunge on hepatitis C drug ANA598 safety concerns _
(http://www.natap.org/2009/EASL/EASL_10.htm) - (04/27/09)
* _Schering's protease boceprevir phase 2; Schering symposium _
(http://www.natap.org/2009/EASL/EASL_09.htm) - (04/27/09)
* _Safety, pharmacokinetics and antiviral effect of BI 207127, a
novel HCV RNA polymerase inhibitor, after 5 days' oral treatment in patients
with chronic hepatitis C _ (http://www.natap.org/2009/EASL/EASL_08.htm) -
(04/27/09)
* _ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels
in Completed Phase Ib Study in Hepatitis C Patients _
(http://www.natap.org/2009/EASL/EASL_07.htm) - (04/24/09)
* _Tibotec HCV Protease TMC435 I Treatment-Naives Genotype 1,
Monotherapy & Combination with Peg/RBV _
(http://www.natap.org/2009/EASL/EASL_06.htm) - (04/24/09)
* _New HCV Drugs II: Schering's protease boceprevir phase 2;
Abbott/Enanta HCV Protease Inhibitors; Progenics PRO-206 HCV Entry Inhibitor _
(http://www.natap.org/2009/EASL/EASL_05.htm) - (04/24/09)
* _Taribavirin vs Ribavirin _
(http://www.natap.org/2009/EASL/EASL_04.htm) - (04/24/09)
* _New HCV Drugs Today at EASL 1st Day _
(http://www.natap.org/2009/EASL/EASL_03.htm) - (04/24/09)
* _EPIC Study Shows Maintenance Therapy Provides Benefits _
(http://www.natap.org/2009/EASL/EASL_02.htm) - (04/23/09)
* _EASL New HCV Drugs_ (http://www.natap.org/2009/EASL/EASL_01.htm)
- (04/23/09)
**************An Excellent Credit Score is 750. See Yours in Just 2 Easy
Steps!
(http://pr.atwola.com/promoclk/100126575x1222585089x1201462806/aol?redir=http://www.freecreditreport.com/pm/default.aspx?sc=668072&hmpgID=62&bcd=Jul
yExcfooterNO62)
|
|
 |
|
